source
- Scribe targets $96 million from Nasdaq IPO as Scholar Rock awaits site classification for apitegromabScribe, a gene-editing biotech, announced plans for a Nasdaq initial public offering that could raise roughly $96 million. The company said it would price the shares at $14 each, which is the midp…
- Latigo Biotherapeutics plans IPO to fund phase 3 trials of non-opioid pain drug LTG-001Latigo Biotherapeutics announced it is preparing an initial public offering to raise capital for its clinical-stage, non-opioid pain management pipeline. The company highlighted its oral Nav1.8 in…